18th Jun 2014 07:47
LONDON (Alliance News) - Hutchison China MediTech Ltd said Wednesday its majority owned research and development company has begun the first in-human Phase I clinical trial of HMPL-523 for autoimmune diseases.
Hutchinson MediPharma Ltd has begun the trial in Australia, with the aim of establishing a safety profile for the treatment. Initial results of the trial are expected around the end of 2014.
HMPL-523 is being developed for the treatment of autoimmune diseases including rheumatoid arthritis and lupus.
Shares in Hutchinson China were trading down 0.2% at 841.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed